Market reactionShares rose 12% on Nov 6.
ArriVent BioPharma is a clinical-stage company developing firmonertinib, an EGFR inhibitor approved in China by its partner Allist, and antibody-drug conjugates; none are approved in the U.S.
ArriVent's investment case depends on finding a path for firmonertinib after FURVENT's primary endpoint miss, advancing ALPACCA in first-line PACC-mutant lung cancer, and developing its ADC portfolio. FURTHER supports PACC development; ALPACCA continues enrolling. Initial ARR-217 responses strengthen the ADC opportunity, although reported response rates include unconfirmed responses. ARR-002 adds another development opportunity. Cash and investments of $373.1 million as of June 30, 2026 were expected to fund operations into 2028, giving management room to prioritize.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: ArriVent finds a path after FURVENT
Can ArriVent establish a viable regulatory path for first-line exon 20 firmonertinib after FURVENT?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
ARR-217 responses strengthen ADC opportunity; firmonertinib's post-FURVENT path remains uncertain
Firmonertinib holds a second-line NSCLC approval; the thesis turns on whether the FURVENT Phase 3 readout unlocks first-line exon 20 insertion labeling
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.